MSN Laboratories launches SEMABEST, India-made semaglutide pen at nearly 50% lower price
CDSCO-approved therapy enters India’s fast-growing post-patent GLP-1 market with fully integrated API, formulation and pen manufacturing
CDSCO-approved therapy enters India’s fast-growing post-patent GLP-1 market with fully integrated API, formulation and pen manufacturing
Subscribe To Our Newsletter & Stay Updated